iShares 1 3 Year Treasury Bond ETF vs Stryker Corporation — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.19 (market cap $26.68B), while Stryker Corporation trades at $277.37 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 4× iShares 1 3 Year Treasury Bond ETF's market cap, and Stryker Corporation pays a 1.27% dividend while iShares 1 3 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 1 3 Year Treasury Bond ETF for 63 Days and Stryker Corporation for 21 Days on average.
| SHY | SYK | |
|---|---|---|
Market Cap | $26.68B | $106.24B |
Volume | 4,077,691 | 2,982,001 |
Sector | Fixed Income | Health |
52-Week High | $83.18 | $388.35 |
52-Week Low | $81.05 | $269.75 |
Typical Hold Time | 63 Days | 21 Days |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
SHY trades at $81.185 with minimal daily movement (+0.03%), reflecting stability amid broader bond market volatility. The technical picture shows a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent dividend payments of $0.24-$0.25 demonstrate consistent income distribution. The fund operates in a challenging environment with rising Treasury yields impacting bond valuations.
SHY faces headwinds from the ongoing bond market selloff and rising interest rates, which pressure short-term bond ETFs. However, the fund's structure provides relative stability compared to longer-duration instruments. The primary risk remains further Fed tightening, while the opportunity lies in capital preservation during market turbulence.
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →